Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral L-arginine for uterine artery resistance in women with recurrent implant failure
IRCT20220317054318N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, single-arm trial of arginine in female infertility, sponsored by Hamadan University of Medical Sciences. Primary endpoint: Change in uterine artery resistance. Started May 2022; status: completed.
02
Drugs
arginine
03
Conditions
female infertility
Beyond the preview
Go deeper on IRCT20220317054318N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220317054318N1.